Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

NACompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2019

Study Completion Date

September 30, 2024

Conditions
Coronary Artery Disease
Interventions
DEVICE

Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold

Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease

Trial Locations (28)

Unknown

The Prince Charles Hospital, Chermside

St Vincent's Hospital Sydney, Darlinghurst

Prince of Wales Hospital (Eastern Heart), Randwick

Cardiovascular Center Aalst, Aalst

Albert Einstein Hospital, São Paulo

Instituto Dante Pazzanese de Cardiologia, São Paulo

Aarhus University Hospital (Skejby), Aarhus

Rigshospitalet, Copenhagen

Odense University Hospital, Odense

institut Hospitalier J.Cartier, Massy

La Pitié-Salpétrière, Paris

Clinique Pasteur, Toulouse

Hôpital Rangueil, Toulouse

Am Urban Hospital, Berlin, Berlin

Friedrichshein Hospital, Berlin, Berlin

Klinikum Coburg, Coburg

St.- Johannes-Hospital Dortmund, Dortmund

Universitätsklinikum Erlangen, Erlangen

Elisabeth-Krankenhaus Essen, Essen

Universitätsklinikum Schleswig-Holstein, Kiel

Academic Medical Center Amsterdam, Amsterdam

Onze Lieve Vrouwe Gasthuis, Amsterdam

Erasmus Medical Center, Rotterdam

University Medical Center Utrecht, Utrecht

Krakowskie Centrum Kardiologii Inwazyjnej, Krakow

Szpital Uniwersytecki w Krakowie, Krakow

Szpital Kliniczny Przemienienia Panskiego UM w Poznaniu, Poznan

Oddział Kardiologii Inwazyjnej I Katedra, Warsaw

All Listed Sponsors
lead

REVA Medical, Inc.

INDUSTRY

NCT02539966 - Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold | Biotech Hunter | Biotech Hunter